Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Embla Medical hf's EBIT per Share for the
three
months ended in Jun. 2026 was kr0.66.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 was kr2.15.
During the past 12 months, the average EBIT per Share Growth Rate of Embla Medical hf was 4.70% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 18.20% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 16.50% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 4.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Embla Medical hf's EBIT per Share or its related term are showing as below:
OCSE:EMBLA'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -10.9 Med: 11.4 Max: 53.7
Current: 18.2
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Embla Medical hf was 53.70% per year. The lowest was -10.90% per year. And the median was 11.40% per year.
OCSE:EMBLA's 3-Year EBIT Growth Rate is ranked better than 62.77% of 685
companies
in the Medical Devices & Instruments industry
Industry Median: 9.6
vs OCSE:EMBLA: 18.20
Embla Medical hf (OCSE:EMBLA) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Embla Medical hf EBIT per Share Related Terms
Embla Medical hf EBIT per Share Historical Data
* Premium members only.
The historical data trend for Embla Medical hf's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr2.15
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Embla Medical hf (OCSE:EMBLA) has a EBIT per Share of kr2.15 as of Jun. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Embla Medical hf and its competitors. According to the industry distribution chart, Embla Medical hf ranks #255 out of 685 companies in the Medical Devices & Instruments industry, placing it in the top 37.2%.
Is Embla Medical hf's EBIT per Share too high?
Embla Medical hf's current EBIT per Share is kr2.15. Based on the distribution chart, Embla Medical hf ranks #255 out of 685 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Embla Medical hf has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Embla Medical hf's EBIT per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Embla Medical hf ranks #255 out of 685 companies for EBIT per Share. This puts Embla Medical hf in the upper half of its industry. The industry median EBIT per Share is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.60, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Embla Medical hf and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Embla Medical hf's current EBIT per Share is kr2.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Embla Medical hf stock overvalued right now?
Based on GuruFocus' analysis, Embla Medical hf (OCSE:EMBLA) is currently considered Modestly Undervalued. The stock's GF Value™ is kr34.14, compared to a current price of kr28.15 — trading 17.5% below its estimated fair value. The current EBIT per Share is kr2.15. Embla Medical hf's overall GF Score™ is 93/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Embla Medical hf (OCSE:EMBLA), the current EBIT per Share is kr2.15 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Embla Medical hf (OCSE:EMBLA) Overvalued in 2026?
Based on GuruFocus' analysis, Embla Medical hf stock appears to be undervalued.
The current stock price of kr28.15 is trading 17.5% below its estimated GF Value™ of kr34.14.
GuruFocus considers Embla Medical hf to be Modestly Undervalued.
Key valuation signals for OCSE:EMBLA:
EBIT per Share: kr2.15
GF Value™: kr34.14 vs. price of kr28.15 (17.5% below fair value)
No single metric tells the full story. See the OCSE:EMBLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Embla Medical hf operates as an orthopedic products company specializing in the design, development, manufacturing and sales of prosthetics and bracing & supports products. The company also provides patient care through a network of Orthotic and Prosthetic (O&P) facilities. It sells its products in multiple countries, with Europe and North America representing its principal markets. The company operates within three business segments: Prosthetics & Neuro Orthotics, Bracing & Supports and Patient Care. The majority of the company's revenue is derived from the Prosthetics & Neuro Orthotics, which includes products designed for users with varying mobility needs, ranging from lower-activity applications to solutions intended for more active use.
93GF Score
Get the complete analysis for OCSE:EMBLA
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:EMBLA has been successfully added to your 
